Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting
May 26 2022 - 5:01PM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a clinical-stage oncology-focused cell therapy company today
announced a Trials in Progress poster presentation at the 2022
American Society of Clinical Oncology Annual Meeting being held in
Chicago, IL June 3-7, 2022.
The Trials in Progress poster presentation will
summarize the adaptive trial design, dosing regimen, and follow up
strategy for Alaunos’ ongoing TCR-T Library Phase 1/2 trial. The
open label, dose escalation trial is being conducted at The
University of Texas MD Anderson Cancer Center and is currently
enrolling patients with non-small cell lung, colorectal,
endometrial, pancreatic, ovarian, and bile duct cancers that have a
matching human leukocyte antigen (HLA) and hotspot mutation pairing
in Alaunos’ TCR-T library. In May 2022, the Company announced that
it had dosed the first patient in the trial.
“We are honored to be selected by the ASCO
Scientific Program Committee to present our adaptive design for our
ongoing TCR-T Library Phase 1/2 trial,” stated Kevin S. Boyle, Sr.
“Leveraging our proprietary non-viral Sleeping Beauty technology
and our growing TCR-T library, we are a leader in the field of
TCR-T cell therapies targeting solid tumors. Our approach attacking
shared hotspot mutations that drive cancer has the potential to
kill tumors. With the first patient successfully dosed we look
forward to sharing an initial look at data later this year as we
continue to enroll additional patients into our study.”
Details of the poster presentation are as
follows:
Poster Presentation: First
in-human phase 1/2 study of autologous T cells engineered using the
Sleeping Beauty System transposon/transposase to express T-cell
receptors (TCRs) reactive against cancer-specific mutations in
patients with advanced solid tumors.Session Title:
Developmental Therapeutics—ImmunotherapySession
Date/Time: Sunday, June 5, 2022, 8:00-11:00am
CDTAbstract Number: TPS2679Poster Board
Number: 328bLocation: McCormick Place,
Exhibit HallAdditional information about the study is available at
www.clinicaltrials.gov using the identifier: NCT05194735.
About Alaunos
TherapeuticsAlaunos is a clinical-stage oncology-focused
cell therapy company, focused on developing T-cell receptor (TCR)
therapies based on its proprietary, non-viral Sleeping Beauty gene
transfer technology and its TCR library targeting shared
tumor-specific hotspot mutations in key oncogenic genes including
KRAS, TP53 and EGFR. The Company has clinical and strategic
collaborations with The University of Texas MD Anderson Cancer
Center and the National Cancer Institute. For more information,
please visit www.alaunos.com.
Forward-Looking Statements
Disclaimer This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as “may,” “will,” “could,” “expects,” “plans,”
“anticipates,” “believes” or other words or terms of similar
meaning. These statements include, but are not limited to,
statements regarding the Company's business and strategic plans,
the Company's cash runway, and the timing of the Company's research
and development programs, including the anticipated dates for
filing INDs, enrolling and dosing patients in and the expected
timing and forums for announcing data and results from the
Company’s clinical trials. Although the management team of Alaunos
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Alaunos, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include, among other
things, changes in the Company’s operating plans that may impact
its cash expenditures; the uncertainties inherent in research and
development, future clinical data and analysis, including whether
any of Alaunos’ product candidates will advance further in the
preclinical research or clinical trial process, including receiving
clearance from the U.S. Food and Drug Administration or equivalent
foreign regulatory agencies to conduct clinical trials and whether
and when, if at all, they will receive final approval from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies and for which indication; the strength and enforceability
of Alaunos’ intellectual property rights; and competition from
other pharmaceutical and biotechnology companies as well as risk
factors discussed or identified in the public filings with the
Securities and Exchange Commission made by Alaunos, including those
risks and uncertainties listed in the most recent periodic report
filed by Alaunos with the Securities and Exchange Commission.
Alaunos is providing this information as of the date of this press
release, and Alaunos does not undertake any obligation to update or
revise the information contained in this press release whether as a
result of new information, future events, or any other reason.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2023 to Apr 2024